By combining AI-driven automation, accuracy, and advanced trauma functionality, mediCAD® 8 defines a new benchmark for intelligent digital surgery planning - empowering surgeons to plan faster, act ...
Avacta Therapeutics (AIM: AVCT, ‘Avacta’, ‘the Company’), a clinical stage biopharmaceutical company developing pre|CISION ®, a tumor-activated oncology delivery platform, today announced the ...
Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, will ...
The COMPARE trial is an open-label, randomized, controlled Phase 1/2 study evaluating KYV-101 against the anti-CD20 monoclonal antibody rituximab in patients with anti-citrullinated protein antibody ...
Durability: VOQUEZNA demonstrated sustained nocturnal symptom relief throughout the full treatment period, consistent with the 24-hour heartburn relief observed in the full pHalcon-NERD-301 trial.
Investor call on Novartis Immunology pipeline Following the conclusion of ACR, Novartis will host a conference call for investors to provide updates on the company’s Immunology pipeline on Thursday, ...
In two oral presentations, data presented from post-hoc analyses evaluated serum uric acid (sUA) levels, joint exam findings, health-related quality-of-life (HRQOL) outcomes, and gout flares in the ...
Dans le même temps, Polpharma Group est heureux d’annoncer la nomination de Sebastian Szymanek au poste de nouveau PDG, à compter du 1er janvier 2026. Sebastian occupe actuellement la fonction de ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback